MARKET

CGEM

CGEM

Cullinan Oncology Inc
NASDAQ
14.81
-0.63
-4.08%
After Hours: 14.81 0 0.00% 19:30 09/25 EDT
OPEN
15.62
PREV CLOSE
15.44
HIGH
15.62
LOW
14.67
VOLUME
1.72M
TURNOVER
--
52 WEEK HIGH
23.19
52 WEEK LOW
5.68
MARKET CAP
953.09M
P/E (TTM)
-4.3457
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: AMN Healthcare Services (AMN) and Cullinan Management (CGEM)
TipRanks · 1d ago
Cullinan Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 1d ago
Cullinan Therapeutics Price Target Raised to $35.00/Share From $30.00 by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Raises Price Target to $35
Benzinga · 1d ago
Cullinan Therapeutics price target raised to $35 from $30 at H.C. Wainwright
TipRanks · 1d ago
Cullinan Therapeutics Price Target Maintained With a $40.00/Share by BTIG
Dow Jones · 1d ago
BTIG Reiterates Buy on Cullinan Therapeutics, Maintains $40 Price Target
Benzinga · 1d ago
Analysts’ Top Healthcare Picks: Kyverna Therapeutics, Inc. (KYTX), ACADIA Pharmaceuticals (ACAD)
TipRanks · 1d ago
More
About CGEM
Cullinan Therapeutics, Inc. is a biopharmaceutical company. It has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors.

Webull offers Cullinan Therapeutics Inc stock information, including NASDAQ: CGEM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGEM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CGEM stock methods without spending real money on the virtual paper trading platform.